RxTrials Earns National Women-Owned Business Certification

ELLICOTT CITY, Md., Jan. 25, 2011 /PRNewswire/ -- RxTrials, Inc., a network of premier clinical research sites and parent company of RxTrials Institute, a leading national clinical research consultant and education provider, has earned status as a Women Business Enterprise (WBE). The WBE certification was presented by the Women's Business Enterprise National Council (WBENC) following a rigorous review process and site visit.

The nationally recognized certification from WBENC helps to maximize opportunities for women owned business to participate in contracting and purchasing activities. WBENC certification tells partnering companies that the business meets a set of national standards and adheres to strong business ethics.

Certification from WBENC often is sought by companies that are leaders in their industries and whose owners wish to demonstrate their commitment to growth and progress for companies that are owned and managed by women.

"Obtaining certification from WBENC was a personal goal of mine for RxTrials to be a voice and encouragement for other women and specifically young women to aspire to realize their dreams," said Christine Pierre, President. "As RxTrials approaches its 16th year in business, it is quite meaningful that we have achieved this goal and have a recognized voice in our industry."

More information about WBENC certification is available online at www.wbenc.org.

About RxTrials, Inc.

RxTrials is a network of premier Investigative Sites that conduct Phase II through Phase IV and vaccine clinical research studies, based in physician practices, clinics and hospitals. Since 1994, RxTrials has successfully completed more than 1,000 studies and is a strategic partner with leading Sponsors and CROs. Through its sister company, RxTrials Institute, RxTrials provides professional training, education and consultation, and sponsors the annual Site Solutions Summit. More information can be found at www.rxtrialsinc.com.

SOURCE RxTrials, Inc.